All In Biotech

Drug Trial Radar · NCT07777549

A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)

A Phase 2a, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRTL-913 in Healthy Adult Volunteers Under Fed Conditions (Part A), and an Open-Label Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy in Adults With Tinnitus (Part B)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Tortugas Neuroscience, Inc.Industry
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and efficacy of a 2-week treatment course in adults with tinnitus.

Conditions

  • Tinnitus

Interventions

  • TRTL-913Drug

    Participants will receive TRTL-913 capsules QD.

  • PlaceboDrug

    Participants will receive TRTL-913 matching placebo capsules QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 16
  2. Part B: Number of Participants With TEAEs and SAEsTime frame: Up to Day 21
  3. Part A: Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Clinical Laboratory Values, and Electrocardiograms (ECGs)Time frame: Up to Day 16
  4. Part B: Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Clinical Laboratory Values, and ECGsTime frame: Up to Day 21
  5. Part A: Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 16
  6. Part B: Number of Participants With Suicidal Ideation or Behavior as Assessed by the C-SSRSTime frame: Up to Day 21

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Newcastle, New South Wales, Australia · Not yet recruiting

  • Clinical Trial Site

    Sydney, New South Wales, Australia · Not yet recruiting

  • Clinical Trial Site

    Waitara, New South Wales, Australia · Not yet recruiting

  • Clinical Trial Site

    Southport, Queensland, Australia · Not yet recruiting

  • Clinical Trial Site

    Torquay, Victoria, Australia · Not yet recruiting

  • Clinical Trial Site

    Auckland, New Zealand · Recruiting

  • Clinical Trial Site

    Christchurch, New Zealand · Not yet recruiting

  • Clinical Trial Site

    Nelson, New Zealand · Not yet recruiting

  • Clinical Trial Site

    Rotorua, New Zealand · Not yet recruiting

  • Clinical Trial Site

    Wellington, New Zealand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.